Haemonetics Corporation (HAE) is putting serious money behind vascular closure technology. The company announced Friday it's acquiring Ireland-based Vivasure Medical Limited for 100 million euros (roughly $117 million) upfront, with another 85 million euros potentially on the table if certain milestones hit.
The strategic play here is straightforward: structural heart and endovascular procedures are growing fast, and those procedures increasingly need large-bore vascular access. That means bigger holes in blood vessels, which means more sophisticated ways to close them up afterward. Vivasure's technology addresses exactly that problem.
The star of the show is PerQseal Elite, a vascular closure system that works from inside the vessel using a proprietary bioabsorbable patch. It handles access sites up to 26F (that's pretty large in medical device terms), and because it's fully absorbable and sutureless, it's designed to make workflows smoother while cutting down complication risks during complex cardiovascular interventions.
Where the Tech Stands Regulatorily
Vivasure submitted a U.S. FDA Premarket Approval application in 2025 for the arterial version of PerQseal Elite. In Europe, the device already has CE Mark approval for both arterial and venous uses, meaning it's commercially available across the pond.
The clinical backing looks solid. Results from the multicenter ELITE arterial study showed zero major complications at 30 days, immediate median time to hemostasis (meaning the bleeding stopped right away), and no need for a pre-close technique. That last bit matters because pre-close adds complexity to procedures.
On the financial mechanics, Haemonetics noted the upfront payment will be adjusted to account for prior investments and loans Vivasure received. The additional consideration is tied to future sales growth and hitting operational targets, which is a fairly standard earn-out structure.
What Management Is Saying
"Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures," said Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics.
The company has the balance sheet to back this up. As of September 27, 2025, Haemonetics had $296.4 million in cash on hand, and it's funding the transaction entirely with existing cash resources.
Looking ahead, Haemonetics will publish its third-quarter fiscal 2026 results on February 5, which should give investors more color on how this acquisition fits into broader capital deployment plans and integration strategy.
HAE Price Action: Haemonetics shares closed 1.25% higher at $84.04 on Thursday. The stock is approaching its 52-week high of $87.32.
